Overview

A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients With Obstructive Sleep Apnea (OSA)

Status:
Recruiting
Trial end date:
2024-10-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of 12-week solriamfetol administration in the treatment of EDS in patients with OSA from China, using a randomized, double-blind, placebo-controlled, multi-center, parallel-design.
Phase:
Phase 3
Details
Lead Sponsor:
Ignis Therapeutics (Suzhou) Limited